The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
 
Sibylle Loibl
Honoraria - Chugai Pharma
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Samsung (Inst); Seagen (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Immunomedics (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent Pending EP14153692.0 (Inst)
 
Andreas Schneeweiss
Honoraria - AstraZeneca; Celgene; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Tesaro
Research Funding - Abbvie; Celgene (Inst); Molecular Partners; Roche Pharma AG (Inst)
Expert Testimony - AstraZeneca; Roche
Travel, Accommodations, Expenses - Celgene; Roche
 
Jens Bodo Huober
Honoraria - Abbvie; AstraZeneca; Celgene; Eisai; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; Hexal; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - Celgene (Inst); Hexal (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Daiichi Sankyo; Novartis; Pfizer; Roche
 
Michael Braun
Honoraria - AstraZeneca; Celgene
Consulting or Advisory Role - AstraZeneca; Celgene
Travel, Accommodations, Expenses - AstraZeneca; Celgene
 
Julia Rey
No Relationships to Disclose
 
Jens U. Blohmer
Honoraria - Amgen; AstraZeneca; MSD Oncology; Novartis; Pfizer; Roche; SonoScape
Consulting or Advisory Role - Amgen; AstraZeneca; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Jenny Furlanetto
No Relationships to Disclose
 
Dirk Michael Zahm
No Relationships to Disclose
 
Claus Hanusch
No Relationships to Disclose
 
Jörg Thomalla
No Relationships to Disclose
 
Christian Jackisch
Honoraria - AstraZeneca; Exact Sciences; Lilly; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Genomic Health; Genomic Health; Novartis; Roche; Tesaro
Research Funding - Genomic Health (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis; Roche
 
Peter Staib
Research Funding - Abbvie; Amgen; AstraZeneca (Inst); Celgene; Gilead Sciences; Janssen-Cilag; Novartis; Pfizer
 
Theresa Link
Honoraria - Amgen; Lilly; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Eisai; Lilly; MSD; Myriad Genetics; Pfizer; Roche; Tesaro
Travel, Accommodations, Expenses - Celgene; Clovis Oncology
 
Kerstin Rhiem
Honoraria - AstraZeneca; MSD; Pfizer
Consulting or Advisory Role - MSD; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; MSD; Pfizer
 
Christine Solbach
Consulting or Advisory Role - Hologic; MSD
Travel, Accommodations, Expenses - AstraZeneca; MSD; Pfizer; Roche
 
Peter A. Fasching
Honoraria - Agendia; AstraZeneca; BionTech (Inst); Cepheid (Inst); Daiichi Sankyo; Eisai; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; AstraZeneca; Daiichi Sankyo; Eisai; Hexal; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - BioNTech (Inst); Cepheid (Inst); Novartis (Inst)
 
Nicole Burchardi
No Relationships to Disclose
 
Carsten Denkert
Stock and Other Ownership Interests - Sividon Diagnostics
Honoraria - Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Merck; Molecular Health; MSD Oncology
Research Funding - Myriad Genetics (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent application WO2020109570A1 - cancer immunotherapy; Patent applications WO2015114146A1 and WO2010076322A1- therapy response; VMScope digital pathology software
Travel, Accommodations, Expenses - Roche
 
Michael Untch
Honoraria - Agendia (Inst); Art tempi (Inst); AstraZeneca (Inst); Bristol Myer Squibb (Inst); Celgene (Inst); Daiji Sankyo (Inst); MSD Oncology (Inst); Mundipharma (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Seagen (Inst)
Consulting or Advisory Role - Abbvie (Inst); Agendia (Inst); Amgen (Inst); Celgene (Inst); Lilly (Inst); MSD Oncology (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche Pharma AG (Inst); Seagen (Inst)